New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2019, WHO consolidated guidelines on drug-resistant tuberculosis treatment
View latest version (2019)Bibliographic Info
Guideline—
Year of Publication—
Issuing Institution—
Recommendation
Status
Retired
Recommended in favor
Conditional
Certainty of evidence
Very low
In patients with isoniazid-resistant, rifampicin-resistant TB or multidrug-resistant TB who were not previously treated with second-line drugs and in whom resistance to fluoroquinolones and second-line injectable agents was excluded or is considered highly unlikely, a shorter MDR-TB regimen of 9–12 months may be used instead of the longer regimens